A Dose Escalation and Cohort Expansion Study of DKN-01 in Combination With Gemcitabine and Cisplatin in Patients With Advanced Carcinoma Primary to the Intra- or Extra-hepatic Biliary System or Gallbladder

Trial Profile

A Dose Escalation and Cohort Expansion Study of DKN-01 in Combination With Gemcitabine and Cisplatin in Patients With Advanced Carcinoma Primary to the Intra- or Extra-hepatic Biliary System or Gallbladder

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 11 Aug 2017

At a glance

  • Drugs DKN 01 (Primary) ; Cisplatin; Gemcitabine
  • Indications Biliary cancer; Cholangiocarcinoma; Gallbladder cancer
  • Focus Adverse reactions
  • Sponsors HealthCare Pharmaceuticals Inc; Leap Therapeutics
  • Most Recent Events

    • 08 Aug 2017 Status changed from recruiting to active, no longer recruiting.
    • 06 Jun 2017 Interim results (n=27) assessing the safety and efficacy of DKN-01 in combination with gemcitabine and cisplatin in patients with advanced biliary tract cancers, presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
    • 17 May 2017 Interim results published in a Leap Therapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top